Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938507 | 1.00 | PPARA (0.47) | PPARAPPARGPTPN1ACEMME | |
| SCHEMBL5007480 | 0.90 | PPARA (0.57) | PPARAPPARGPTPN1ACEMME | |
| SCHEMBL4767235 | 0.90 | PPARA (0.57) | PPARAPPARGPTPN1ACEMME | |
| SCHEMBL5007445 | 0.81 | PPARA (0.57) | PPARAPPARGPTPN1ACECTSS | |
| SCHEMBL5007446 | 0.81 | PPARA (0.57) | PPARAPPARGPTPN1ACECTSS | |
| SCHEMBL5227731 | 0.80 | PPARA (0.71) | PPARAPPARGPTPN1ACEMME | |
| SCHEMBL5247747 | 0.80 | PPARA (0.71) | PPARAPPARGPTPN1ACEMME | |
| SCHEMBL5001273 | 0.79 | PPARA (0.55) | PPARAPPARGPTPN1ACECTSS | |
| SCHEMBL5001277 | 0.79 | PPARA (0.55) | PPARAPPARGPTPN1ACECTSS | |
| SCHEMBL5007491 | 0.79 | PPARA (0.55) | PPARAPPARGPTPN1ACECTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0989993-B1 | TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS GROWTH HORMONE SECRETAGOGUE | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | disclosed |
| CN-1837205-A | Process for the preparation of pyrazolopyridine tartrates | PFIZER PROD INC (US) | 2006-09-27 | — | — | CN | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| US-6867202-B1 | Increasing level of endogenous growth hormone using growth hormone secretagogue such as 2-amino-N-(2-(3a-benzyl-2-methy-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-(4,3 -c)pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl)-isobutyramide tartarate salt | PFIZER INC. (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1031575-B1 | Process for preparing growth hormone secretagogues | PFIZER PROD INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1449842-A1 | Process for the preparation of pyrazolopyridine tartrates | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| CN-1515570-A | Preparation method of pyrazolo [4, 3-c ] pyridine-3-ketone L-tartrate | �Ʒ� | 2004-07-28 | — | — | CN | disclosed |
| CN-1137891-C | Process for preparing growth hormone secretagogue | �Ʒ� | 2004-02-11 | — | — | CN | disclosed |
| US-6673929-B2 | Process for preparing growth hormone secretagogues | PFIZER INC. | 2004-01-06 | — | — | US | disclosed |
| US-6630487-B2 | Treatment of insulin resistance with growth hormone secretagogues | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6541634-B2 | Reacting a pyrazolo(4,3-a)pyridine compound with amine | PFIZER INC. | 2003-04-01 | — | — | US | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020002283-A1 | Process for preparing growth hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-20010016570-A1 | Tartrate salt of a substituded dipeptide as growth hormone secretagogue | RAQUALIA PHARMA INC. (JP) | 2001-08-23 | — | — | US | disclosed |
| US-6248717-B1 | TREATMENT OF OSTEOPOROSIS, CARDIOTONIC AGENTS, ANTIAGING AGENTS, WOUND HEALING AGENTS | PFIZER INC. | 2001-06-19 | — | — | US | disclosed |
| EP-1085867-A1 | THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY | Pfizer Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| CN-1270960-A | Process for preparing growth hormone secretagogue | PFIZER PROD INC (US) | 2000-10-25 | — | — | CN | disclosed |
| EP-1031575-A1 | Process for preparing growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999065488-A1 | THERAPEUTIC COMBINATIONS OF (SELECTIVE) ESTROGEN RECEPTOR MODULATORS (SERM) AND GROWTH HORMONE SECRETAGOGUES (GHS) FOR TREATING MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010016570-A1 | Tartrate salt of a substituded dipeptide as growth hormone secretagogue | GHSR, PTMS, GIPR | PPARA 476/4885PPARG 420/4885PTPN1 1106/4885 |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | PPARA 725/4885PPARG 284/4885PTPN1 2188/4885 |
| US-20020002283-A1 | Process for preparing growth hormone secretagogues | GHRHR, GHSR, PRLHR | PPARA 3080/4885PPARG 1843/4885PTPN1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.